Why this chain matters

AstraZeneca PLC (AZN) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when AZN performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to AZN's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • Ionis Pharmaceuticals, Inc. (IONS) - confidence 92%.
  • Harvard Bioscience, Inc. (HBIO) - confidence 92%.
  • Ironwood Pharmaceuticals, Inc. (IRWD) - confidence 92%.
  • Compugen Ltd. (CGEN) - confidence 92%.
  • Kyntra Bio, Inc. (KYNB) - confidence 85%.
  • Kiniksa Pharmaceuticals International, plc (KNSA) - confidence 72%.
  • Crinetics Pharmaceuticals, Inc. (CRNX) - confidence 72%.
  • Arcus Biosciences, Inc. (RCUS) - confidence 72%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • IDEAYA Biosciences, Inc. (IDYA) - confidence 92%.
  • Fortress Biotech, Inc. (FBIO) - confidence 90%.
  • Silence Therapeutics plc (SLN) - confidence 90%.
  • Cellectis S.A. (CLLS) - confidence 90%.
  • Innate Pharma S.A. (IPHA) - confidence 90%.
  • Allarity Therapeutics, Inc. (ALLR) - confidence 72%.
  • Greenwich LifeSciences, Inc. (GLSI) - confidence 72%.
  • Cytokinetics, Incorporated (CYTK) - confidence 72%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • AZN-OWNER-GOLDMAN-SACHS-GROUP-INC: 13F/ownership overlay lists Goldman Sachs Group Inc; shares held 13,671,749; ownership 0.52%; value $2.6B; as of 2025-09-30.
  • AZN-OWNER-PACER-ADVISORS-INC: 13F/ownership overlay lists Pacer Advisors, Inc.; shares held 15,863; value $3.0M; as of 2025-09-30.
  • AZN-OWNER-FMR-LLC: 13F/ownership overlay lists FMR, LLC; shares held 21,686,320; ownership 0.83%; value $4.1B; as of 2025-09-30.
  • AZN-OWNER-FISHER-ASSET-MANAGEMENT-LLC: 13F/ownership overlay lists Fisher Asset Management, LLC; shares held 21,162,724; ownership 0.81%; value $4.0B; as of 2025-09-30.
  • AZN-OWNER-FRANKLIN-RESOURCES-INC: 13F/ownership overlay lists Franklin Resources, Inc.; shares held 19,714,165; ownership 0.75%; value $3.7B; as of 2025-09-30.

Who benefits and who is exposed

If AstraZeneca PLC outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If AZN struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.